Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan

Abstract

Spanish

French

Background:

The benefits of angiotensin II receptor blockers (ARBs) in patients with heart failure who are treated with standard pharmacotherapy, including an angiotensin-converting enzyme (ACE) inhibitor, were demonstrated in 2 large randomized trials. It is currently impossible to determine which patient will benefit from the addition of an ARB.

Objective:

To explore the impact of selected candidate genes on the hemodynamic, neurohormonal, and antiinflammatory effects of candesartan in patients with heart failure who are already being treated with an ACE inhibitor.

Methods:

We investigated the impact of 10 candidate genetic polymorphisms on the effects of candesartan in patients with heart failure who are treated with an ACE inhibitor. We evaluated their impact on acute (2 wk) and long-term (24 wk) changes in blood pressure and N-terminal proB-type natriuretic peptide (NT-proBNP) and high sensitivity C-reactive protein (hsCRP) during treatment with candesartan.

Results:

Thirty-one patients were included. Homozygotes of the AGTR1 A1166 allele (n = 13) had a greater decrease in systolic (-9.1 ± 4.7 vs 1.1 ± 3.3 mmHg; p = 0.04 by analysis of variance [ANOVA], adjusting for dose) and diastolic blood pressure (-5.1 ± 1.5 vs 1.9 ± 1.9 mm Hg; p = 0.005 by ANOVA, adjusting for dose) compared with C1166 allele carriers (n = 18) following 2 weeks of treatment. After 6 months of treatment, C1166 carriers experienced a greater decrease in NT-proBNP (-151.4 (-207; -19.8] ng/L vs 147.3 (-61.3; 882.9] ng/L; P = 0.03) and hsCRP (-0.8 [-2.2; -0.03] mg/L) vs 0.2 [-1.8; 5.3] mg/L; p = 0.09) compared with patients carrying the AA1166 genotype. No other significant association was found.

Conclusions:

The results of this proof-of concept study provide the first evidence that the AGTR1 A1166C polymorphism could influence the response to candesartan in patients with heart failure who are receiving ACE inhibitors. Validation of these exploratory findings in larger populations is required before use of the AGTR1 A1166C genotype can be incorporated into clinical practice.

Keywords

angiotensin candesartan heart failure pharmacogenetics

Get full access to this article

View all access options for this article.

References

Martineau

, Goulet

New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure. DOI 10.1345/aph.19307

Farquharson

, Struthers

. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767–75.

McMurray

, Ostergren

, Swedberg

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71.

Cohn

, Tognoni

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75.

Lee

, Peneina

, Benjamin

. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006;355:138–47.

Rice

, Jones

, Grant

, Carter

, Turner

, Hooper

. Circulating activities of angiotensin-converting enzyme, its homolog, angio-tensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006;48:914–20.

McNamara

, Holubkov

, Postava

Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004;44:2019–26.

Ozdemir

, Williams-Jones

, Cooper

, Someya

, Godard

Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 2007;8:177–85.

White

, Lepage

, Lavoie

Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail 2007;13:86–94.

10.

Hallberg

, Lind

, Michaelsson

B₂ bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2003;21:621–4.

11.

Kurland

, Melhus

, Karlsson

Polymorphisms in the angiotensinogen and angiotensin FI type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002;20:657–63.

12.

Kurland

, Melhus

, Karlsson

Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002;15:389–93.

13.

Rigat

, Hubert

, Alhenc-Gelas

, Cambien

, Corvol

, Soubrier

An insertion/deletion polymorphism in the angiotensin I–converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–6.

14.

Grant

, Romero

, Jeunemaitre

Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism. Hypertension 2002;39:191–6.

15.

McNamara

, Holubkov

, Postava

Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 2003;107:1598–602.

16.

Forleo

, Resta

, Sorrentino

Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004;117:451–8.

17.

Fernandez-Llama

, Poch

, Oriola

, Botey

, Rivera

, Revert

Angiotensinogen gene M235T and T174M polymorphisms in essential hypertension: relation with target organ damage. Am J Hypertens 1998;11:439–44.

18.

Kupari

, Hautanen

, Lankinen

Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569–75.

19.

Braun

, Kammerer

, Bohme

, Muller

, Roscher

. Identification of polymorphic sites of the human bradykinin B₂ receptor gene. Biochem Biophys Res Commun 1995;211:234–40.

20.

Morrison

, Doris

, Folsom

, Nieto

, Boerwinkle

G-protein beta3 subunit and alpha-adducin polymorphisms and risk of subclinical and clinical stroke. Stroke 2001;32:822–9.

21.

Hibi

, Ishigami

, Tamura

Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998;32:521–6.

22.

Fatini

, Sofi

, Sticchi

Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. Am Heart J 2004;147:516–21.

23.

Kaye

, Smirk

, Williams

, Jennings

, Esler

, Holst

Betaadrenoceptor genotype influences the response to Carvedilol in patients with congestive heart failure. Pharmacogenomics 2003;13:379–82.

24.

Shanmugam

, Sell

, Saha

. Mistyping ACE heterozygotes. PCR Methods Appl 1993;3:120–1.

25.

Araujo

, Goulart

, Cordeiro

. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. Int J Cardiol 2005;103:27–32.

26.

Hingorani

, Brown

. A simple molecular assay for the C1 166 variant of the angiotensin II type 1 receptor gene. Biochem Biophys Res Commun 1995;213:725–9.

27.

Schmidt

, Beige

, Walla-Friedel

, Michel

, Sharma

, Ritz

A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension. J Hypertens 1997;15:1385–8.

28.

Anand

, Florea

, Fisher

Surrogate end points in heart failure. J Am Coll Cardiol 2002;39:1414–21.

29.

Baudin

Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 2005;90:277–82.

30.

Spiering

, Kroon

, Fuss-Lejeune

, Daemen

, de Leeuw

. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(l 166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000;36:411–6.

31.

van Geel

, Pinto

, Voors

. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000;35:717–21.

32.

Tiret

, Bonnardeaux

, Poirier

Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910–3.

33.

Kainulainen

, Perola

, Terwilliger

Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 1999;33:844–9.

34.

Belz

. Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II ATI receptor antagonists in clinical pharmacology. Br J Clin Pharmacol 2003;56:3–10.

35.

Spiering

, Kroon

, Fuss-Lejeune

, de Leeuw

. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005;23:753–8.

36.

de Denus

, Pharand

, Williamson

. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 2004;125:652–68.

37.

Anand

, Latini

, Florea

. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428–34.

38.

Miller

, Thai

, Scholey

. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999;56:2173–80.

39.

Redon

, Luque-Otero

, Martell

, Chaves

. Renin–angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenetics J 2005;5:14–20.

40.

Kurland

, Melhus

, Karlsson

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001;19:1783–7.

41.

Bleske

. Evolution and pathophysiology of chronic systolic heart failure. Pharmacotherapy 2000;20(suppl):349S–58S.

42.

Francis

, Benedict

, Johnstone

. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724–9.

43.

Julius

, Nesbitt

, Egan

. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685–97.

44.

McClellan

, Goa

. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998;56:847–69.

45.

Serneri

, Boddi

, Cecioni

Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001;88:961–8.

46.

Swedberg

, Eneroth

, Kjekshus

, Snapinn

Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol 1990;66:40D–4D.

47.

Cohen Solai

, Jondeau

, Beauvais

, Berdeaux

Beneficial effects of Carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail 2004;6:463–6.